PT - JOURNAL ARTICLE AU - Sharma, Daya Nand AU - Guleria, Randeep AU - Wig, Naveet AU - Mohan, Anant AU - Rath, Goura Kisor AU - Subramani, Vellaiyan AU - Bhatnagar, Sushma AU - Mallick, Supriya AU - Sharma, Aman AU - Patil, Pritee AU - Madan, Karan AU - Soneja, Manish AU - Thulkar, Sanjay AU - Singh, Angel Rajan AU - Singh, Sheetal TI - Low Dose Radiation Therapy for COVID-19 Pneumonia: A Pilot Study AID - 10.1101/2020.11.16.20231514 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.16.20231514 4099 - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20231514.short 4100 - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20231514.full AB - Background The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) as pandemic in March 2020. Currently there is no vaccine or specific effective treatment for COVID-19. The major cause of death in COVID-19 is severe pneumonia leading to respiratory failure. Radiation in low doses (<100 cGy) has been known for its anti-inflammatory effect and therefore, low dose radiation therapy (LDRT) to lungs can potentially mitigate the severity of pneumonia and reduce mortality. We conducted a pilot trial to study the feasibility and clinical efficacy of LDRT to lungs in the management of patients with COVID-19.Methods From June to Aug 2020, we enrolled 10 patients with COVID-19 having moderate to severe risk disease [National Early Warning Score (NEWS) of ≥5]. Patients were treated as per the standard COVID-19 management guidelines along with LDRT to both lungs with a dose of 70cGy in single fraction. Response assessment was done based on the clinical parameters using the NEWS.Results All patients completed the prescribed treatment. Nine patients had complete clinical recovery mostly within a period ranging from 3-7 days. One patient, who was a known hypertensive, showed clinical deterioration and died 24 days after LDRT. No patients showed the signs of acute radiation toxicity.Conclusion Results of our study (90% response rate) suggest the feasibility and clinical effectiveness of LDRT in COVID-19 patients having moderate to severe risk disease. This mandates a randomized controlled trial to establish the clinical efficacy of LDRT in COVID-19 pneumonia.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov NCT04394793Clinical Protocols https://clinicaltrials.gov Funding StatementFunding : NoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval of the study was provided by Institute Ethics Committee, All India Institute of Medical Sciences, New Delhi (Ref. No. IEC-465/22.05.2020, RP-01/2020 dated 26th May 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available by authors on request.